PHOSPHONATES AS INHIBITORS OF ENPP1 AND CDNP
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Mar 27, 2025
app pub date -
Dec 8, 2021
filing date -
Dec 8, 2021
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Compounds having activity as inhibitors of ENPP1, CdnP, or both are provided herein. Some embodiments provide compounds having one of the following Structures (I) or (II): or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof, wherein R1, R2, R3, R4, R5, R6, R7a, R7b, R7b, R7c, R25, R26, R27a, R27b, R27c, L1, L5, L6, G1, G2, G3 and G6 are as defined herein. This disclosure provides methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds, and methods for treating disorders associated with ENPP1, including uncontrolled cellular proliferation, cancer and virial or bacterial infections in a mammal.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully